Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more
Zevra Therapeutics Inc. (ZVRA) - Net Assets
Latest net assets as of September 2025: $133.16 Million USD
Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) has net assets worth $133.16 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($270.12 Million) and total liabilities ($136.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $133.16 Million |
| % of Total Assets | 49.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.99 |
Zevra Therapeutics Inc. - Net Assets Trend (2012–2024)
This chart illustrates how Zevra Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual net assets of Zevra Therapeutics Inc. from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $39.67 Million | -35.88% |
| 2023-12-31 | $61.86 Million | -17.65% |
| 2022-12-31 | $75.12 Million | -40.91% |
| 2021-12-31 | $127.12 Million | +291.41% |
| 2020-12-31 | $-66.41 Million | +10.80% |
| 2019-12-31 | $-74.46 Million | -11.85% |
| 2018-12-31 | $-66.57 Million | -15.73% |
| 2017-12-31 | $-57.52 Million | -207.64% |
| 2016-12-31 | $-18.70 Million | -84.72% |
| 2015-12-31 | $-10.12 Million | +58.35% |
| 2014-12-31 | $-24.30 Million | -0.14% |
| 2013-12-31 | $-24.27 Million | -3769.04% |
| 2012-12-31 | $-627.22K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zevra Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48480984600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.01% |
| Other Comprehensive Income | $631.00K | 1.59% |
| Other Components | $544.32 Million | 1372.26% |
| Total Equity | $39.67 Million | 100.00% |
Zevra Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Zevra Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Maling Aquarius Co Ltd
SHG:600073
|
$516.26 Million |
|
Sakura Development Co Ltd
TW:2539
|
$516.37 Million |
|
China Everbright Limited
PINK:CEVIF
|
$516.63 Million |
|
Ardmore Shpng
NYSE:ASC
|
$516.76 Million |
|
Ai Holdings Corporation
PINK:AIHZF
|
$516.06 Million |
|
Beijing North Star Co Ltd Class A
SHG:601588
|
$515.76 Million |
|
Gielda Papierow Wartosciowych w Warszawie SA
WAR:GPW
|
$515.70 Million |
|
Alexanders Inc
NYSE:ALX
|
$515.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zevra Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 61,864,000 to 39,666,000, a change of -22,198,000 (-35.9%).
- Net loss of 105,511,000 reduced equity.
- New share issuances of 64,516,000 increased equity.
- Other comprehensive income increased equity by 674,000.
- Other factors increased equity by 18,123,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-105.51 Million | -266.0% |
| Share Issuances | $64.52 Million | +162.65% |
| Other Comprehensive Income | $674.00K | +1.7% |
| Other Changes | $18.12 Million | +45.69% |
| Total Change | $- | -35.88% |
Book Value vs Market Value Analysis
This analysis compares Zevra Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-4.22 | $9.90 | x |
| 2013-12-31 | $-49.63 | $9.90 | x |
| 2014-12-31 | $-31.59 | $9.90 | x |
| 2015-12-31 | $-21.98 | $9.90 | x |
| 2016-12-31 | $-20.49 | $9.90 | x |
| 2017-12-31 | $-62.80 | $9.90 | x |
| 2018-12-31 | $-59.40 | $9.90 | x |
| 2019-12-31 | $-40.17 | $9.90 | x |
| 2020-12-31 | $-16.68 | $9.90 | x |
| 2021-12-31 | $4.27 | $9.90 | x |
| 2022-12-31 | $2.18 | $9.90 | x |
| 2023-12-31 | $1.74 | $9.90 | x |
| 2024-12-31 | $0.86 | $9.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zevra Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -266.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -446.85%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 4.49x
- Recent ROE (-266.00%) is below the historical average (-29.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.69K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.80 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.02 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-53.65 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.65 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.63 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.81 Million |
| 2019 | 0.00% | -191.00% | 1.22x | 0.00x | $-17.08 Million |
| 2020 | 0.00% | -96.03% | 1.19x | 0.00x | $-6.12 Million |
| 2021 | -6.73% | -29.86% | 0.22x | 1.05x | $-21.27 Million |
| 2022 | -35.64% | -263.48% | 0.09x | 1.54x | $-34.28 Million |
| 2023 | -74.44% | -167.69% | 0.16x | 2.79x | $-52.24 Million |
| 2024 | -266.00% | -446.85% | 0.13x | 4.49x | $-109.48 Million |
Industry Comparison
This section compares Zevra Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zevra Therapeutics Inc. (ZVRA) | $133.16 Million | 0.00% | 1.03x | $516.25 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |